60 Degrees Pharmaceuticals Outlines Tafenoquine Progress and Potential 2027 FDA Filing

60 Degrees Pharmaceuticals (SXTP) updated investors on tafenoquine for babesiosis, noting a blinded study to unblind in January 2027, three confirmed cures, and a potential 2027 FDA filing. Early chronic-study screening showed genus-level signals in 2 of 9 patients, but no positive B. microti results.

Original reporting
Published Oct 23, 2026, 12:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 12:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
60 Degrees Pharmaceuticals Outlines Tafenoquine Progress and Potential 2027 FDA Filing — source image
Decision brief

The 30-second read

$SXTPBullishMed
01

Why it matters

The disclosed trial data and planned FDA filing provide a concrete catalyst that could re‑price the company's valuation.

02

Market read

New clinical data and a clear regulatory timeline create a near‑term trading catalyst for SXTP.

03

What to watch

Potential competition from other antiparasitic candidates and the uncertainty of the CNPV regulatory pathway.

Relevance 7/10Novelty 8/10Timing: immediate

Background

60 Degrees Pharmaceuticals is a small-cap biotech focused on antiparasitic drugs, recently updating its tafenoquine program for babesiosis.

Company-level read

Ticker impact

$SXTPBullishHigh confidence
Context

60 Degrees Pharmaceuticals disclosed new tafenoquine trial data and a planned supplemental FDA filing for 2027.

Expected impact

likely upward pressure as market prices in the upcoming FDA filing potential

Evidence & confidence

First disclosure of trial outcomes and a concrete regulatory timeline provides fresh material for valuation.

Market effects

May boost sentiment toward the broader babesiosis treatment space and related antiparasitic biotech firms.

Limited to U.S. biotech investors; no broader regional effect.

Low; relevance confined to niche infectious‑disease biotech segment.

Counterpoint

If trial signals are weak or the FDA path stalls, the stock could face disappointment despite the headline progress.

Key entities

  • 60 Degrees Pharmaceuticals

    Biotech developer of tafenoquine for babesiosis.

Related articles

$SXTPHighAI 9/10

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On November 19, 2026, 60 Degrees Pharmaceuticals, Inc.…

60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Other Events. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On November 19, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Na

$SXTPMedAI 8/10

60 Degrees Reports Negative Babesia PCR Results In Completed Expanded Access Patients; Stock Down

60 Degrees Pharmaceuticals (SXTP) reported negative PCR results in 5 patients from its expanded access study of tafenoquine for babesiosis, with 4 also testing negative on a sensitive NAT test. All patients showed clinical improvement. The stock is down 29% to $0.60. The company expects to unblind a separate study in January 2027. Tafenoquine is not FDA-approved for babesiosis.

$SXTPMedAI 8/10

60 Degrees Pharmaceuticals (SXTP) Reports PCR-Negative Outcomes in 5 Babesiosis Patients

60 Degrees Pharmaceuticals (SXTP) reported that all 5 completed patients in its expanded access study showed clinical improvement and tested negative for Babesia via PCR, with 4/5 also NAT-negative post-treatment. The company may seek accelerated FDA approval using NAT nonreactivity as a surrogate. Two additional patients are currently being treated, with a total enrollment of 7. The study remains open pending potential FDA discussions.

$SXTPMedAI 8/10

All five patients reported improvement; a sensitive post-treatment test found no parasite in four.

60 Degrees Pharmaceuticals reported that all five patients in its expanded access study for relapsing babesiosis showed significant improvement and tested negative for the parasite. Four of five patients also tested negative on highly sensitive NAT testing. The study evaluates tafenoquine-containing regimens and remains open with seven patients enrolled. The company plans to discuss potential FDA approval pathways.

$SXTPMedAI 8/10

60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients

60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients ● All five completed patients (100%) reported much or very much improved clinical outcomes and tested negative for Babesia on